Introduction: Gliomas are infiltrative primary brain tumours that account for approximately one-third of all central nervous system tumours. The more recent discovery of isocitrate dehydrogenase (IDH) mutations in the gliomas represented major step forward in the molecular characterization of gliomas. IDH mutated glioma have better prognosis and more chemosensitive. MR perfusion is another way of assessment of gliomas which analyse the tumor vascularity. Present study was planned to see any association between MR perfusion parameter (rCBV) and IDH mutation status of gliomas. Material and methods: This prospective observational was done at a tertiary care hospital. Study included 24 patients of brain glioma. Preoperative MRI brain with MR perfusion done in all cases. Post operative immunohistochemistry for IDH mutation done in all cases gliomas. Observation and Results: 24 cases of gliomas were assessed preoperatively by MRI brain and MR perfusion. Regional CBV was assessed in all cases of gliomas. IDH mutation was also assessed post operatively. Mutated group showed the low rCBV (mean - 1.34) in tumor on as compared to nonmutated group. (rCBV- 1.95) with significant P value. (p value<0.003). Conclusion: IDH mutant gliomas have favourable prognosis and associated with low tumor vascularity as assessed by MR perfusion. Thus Perfusion MRI can be used as non-invasive means of obtaining functional information about brain tumor vascularity and IDH mutation status. Prediction of IDH mutant status can be done by rCBV values obtained by MR perfusion in future, however more studies with large number of subject needed for further evaluation.